Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Recently, The Lancet published a phase 3 clinical trial highlighting a promising new treatment for type 2 diabetes. Specifically, the ACHIEVE-3 study evaluated orforglipron, an innovative non-peptide GLP-1 receptor agonist, directly against oral semaglutide. The trial encompassed 1,698 adult patients…
GLP-1 receptor agonists represent a significant advancement in metabolic pharmacology. These agents effectively manage type 2 diabetes and chronic obesity through targeted hormonal mimicry. Clinical application necessitates a thorough understanding of the side effect profile over time. This article analyzes…
Clinical Relevance of Glucagon-Like Peptide 1 Receptor Agonists Insulin resistance remains a primary driver of metabolic dysfunction. Glucagon-like peptide 1 receptor agonists offer a solution. These medications address the root causes of glucose intolerance. Patients with obesity often exhibit impaired…